Provided by Tiger Fintech (Singapore) Pte. Ltd.

ANTENGENE-B

7.900
+0.3905.19%
Volume:12.22M
Turnover:94.81M
Market Cap:5.36B
PE:-14.04
High:7.980
Open:7.510
Low:7.370
Close:7.510
52wk High:8.140
52wk Low:0.530
Shares:679.00M
HK Float Shares:679.00M
Volume Ratio:0.74
T/O Rate:1.80%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.563
ROE:-25.98%
ROA:-13.05%
PB:6.40
PE(LYR):-14.04
PS:58.16

Loading ...

Company Profile

Company Name:
ANTENGENE-B
Exchange:
SEHK
Establishment Date:
2017
Employees:
152
Office Location:
Zhongshan SOHO Plaza,Suites 1206-1209,Block B, 1065 West Zhongshan Road,Changning District,Shanghai,China
Zip Code:
200051
Fax:
86 21 3250 1062
Introduction:
Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.

Directors

Name
Position
MEI Jian Ming
Chairman of the Board,Executive Director,Member of the Remuneration and Assessment Committee,Chairman of the Nomination Committee,科学委员会委员
LONG Zhen Guo
Executive Director
QIAN Jing
Independent Director,Chairman of the Remuneration and Assessment Committee,Member of the Nomination Committee,Audit Committee Member
TANG Sheng
Independent Director,Member of the Remuneration and Assessment Committee,Audit Committee Chairman
Rafael Fonseca
Independent Director,Member of the Nomination Committee,Audit Committee Member,科学委员会主席

Shareholders

Name
Position
MEI Jian Ming
CEO
LONG Zhen Guo
CFO
LIU Yi Teng
COO
CAO Yang
Corporate Secretary
HUANG Wei Chao
Corporate Secretary
ZHANG Xiao Jing
Other Senior Executives